Glioma is the most pervasive intracranial tumor in the central nervous system (CNS), with glioblastoma (GBM) being the most malignant type having a highly heterogeneous cancer cell population. There is a significantly high mortality rate in GBM patients. Molecular biomarkers related to GBM malignancy may have prognostic values in predicting survival outcomes and therapeutic responses, especially in patients with high-grade gliomas. In particular, N6-methyladenine (m6A) mRNA modification is the most abundant form of post-transcriptional RNA modification in mammals and is involved in regulating mRNA translation and degradation. Cumulative findings indicate that m6A methylation plays a crucial part in neurogenesis and glioma pathogenesis. In this review, we summarize recent advances regarding the functional significance of m6A modification and its regulatory factors in glioma occurrence and progression. Significant advancement of m6A methylation-associated regulators as potential therapeutic targets is also discussed.

中文翻译：

---

N6-甲基腺苷甲基化在神经胶质瘤中的作用：最新见解和未来方向

胶质瘤是中枢神经系统（CNS）中最普遍的颅内肿瘤，其中胶质母细胞瘤（GBM）是恶性程度最高的类型，具有高度异质性的癌细胞群。GBM 患者的死亡率非常高。与 GBM 恶性肿瘤相关的分子生物标志物可能在预测生存结果和治疗反应方面具有预后价值，特别是对于高级别胶质瘤患者。特别是，N6-甲基腺嘌呤 (m6A) mRNA 修饰是哺乳动物中最丰富的转录后 RNA 修饰形式，参与调节 mRNA 翻译和降解。累积的研究结果表明 m6A 甲基化在神经发生和神经胶质瘤发病机制中发挥着至关重要的作用。在这篇综述中，我们总结了 m6A 修饰的功能意义及其在神经胶质瘤发生和进展中的调节因素的最新进展。还讨论了 m6A 甲基化相关调节因子作为潜在治疗靶点的重大进展。